Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Izastobart (HIB210) in Healthy Volunteers
NCT05928585Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing MAD HIB210 with MAD Placebo (2 arms). Primary endpoints: Number of participants with adverse events, Number of participants with clinical laboratory abnormalities and 3 more. Started Jul 2023; status: completed.
02
Drugs
izastobart
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05928585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928585.